Carisma Therapeutics Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Unaudited Consolidated Balance Sheets

In millions of USD; shares in millions, except per-share amounts

	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020
Assets
Current assets:
Cash and cash equivalents
Accounts receivable
Marketable securities
Restricted cash
Accounts receivables
Other receivables
Prepaid expenses and other assets
Assets held for sale
Total current assets

Marketable securities
Intangible assets
Goodwill
Long term prepaid expenses
Other assets
Total non-current assets
Property and equipment, net
Right of use assets - operating leases
Restricted cash
Deferred financing costs
Total assets

Liabilities and Stockholders' Deficit
Current liabilities:
Accounts payable
Accrued expenses
Contingent consideration
Deferred revenue
Operating lease liabilities
Finance lease liabilities
Other current liabilities
Total current liabilities

Contingent consideration
Deferred tax liability
Total non-current liabilities
Deferred revenue
Convertible promissory note
Derivative liability
Operating lease liabilities
Finance lease liabilities
Other long-term liabilities
Total liabilities
Convertible preferred stock
Stockholders' deficit:
Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding
Common stock, shares outstanding (in shares)
Common stock $0.001 par value, 350,000,000 shares authorized, 41,788,096 and 41,750,109 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total Carisma Therapeutics Inc. stockholders’ equity (deficit)
Noncontrolling interests
Total stockholders' deficit
Total liabilities and stockholders' deficit
Common stock, shares issued (in shares)

Comments